This study identifies CEACAM6 as a robust predictive biomarker for neoadjuvant chemotherapy (NAC) response in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.